[go: up one dir, main page]

AR065564A1 - Composiciones farmaceuticas que comprenden un agente calciletico - Google Patents

Composiciones farmaceuticas que comprenden un agente calciletico

Info

Publication number
AR065564A1
AR065564A1 ARP080100861A ARP080100861A AR065564A1 AR 065564 A1 AR065564 A1 AR 065564A1 AR P080100861 A ARP080100861 A AR P080100861A AR P080100861 A ARP080100861 A AR P080100861A AR 065564 A1 AR065564 A1 AR 065564A1
Authority
AR
Argentina
Prior art keywords
rapid
agent
pharmaceutical composition
short
subject
Prior art date
Application number
ARP080100861A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38016483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR065564A1 publication Critical patent/AR065564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica, la cual comprende un agente calcilítico que, cuando se administra oralmente a un sujeto, induce una liberacion rápida y de corta duracion de hormona paratiroidea en e! plasma. Además se proporciona una composicionfarmacéutica que comprende un agente calcilítico que, cuando se administra oralmente a un sujeto, da como resultado una rápida absorcion del agente calcilítico, con un aumento rápido y de corta duracion subsiguiente de sus niveles en plasma. Ademásse proporciona una composicion farmacéutica que comprende un agente calcilítico que, cuando se administra oralmente a un sujeto, induce una absorcion rápida y de corta duracion del agente calcilítico, y una liberacion rápida de y corta duracion dela hormona paratiroidea. Reivindicacion 7: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, la cual comprende además un medio de vehículo que comprende un componente lipofílico, un tensoactivo, y uncomponente hidrofílico. Reivindicacion 8: Una composicion de acuerdo con la reivindicacion 7, en donde el medio de vehículo comprende además un co-solvente. Reivindicacion 12: La composicion de acuerdo con cualquiera de las reivindicaciones 8 a11, en donde el co-solvente comprende etanol.
ARP080100861A 2007-03-02 2008-02-29 Composiciones farmaceuticas que comprenden un agente calciletico AR065564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103365A EP1964548A1 (en) 2007-03-02 2007-03-02 Pharmaceutical compositions comprising a calcilytic agent

Publications (1)

Publication Number Publication Date
AR065564A1 true AR065564A1 (es) 2009-06-17

Family

ID=38016483

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100861A AR065564A1 (es) 2007-03-02 2008-02-29 Composiciones farmaceuticas que comprenden un agente calciletico

Country Status (20)

Country Link
US (1) US20100022565A1 (es)
EP (2) EP1964548A1 (es)
JP (1) JP2010520179A (es)
KR (1) KR20090125245A (es)
CN (1) CN101621993A (es)
AR (1) AR065564A1 (es)
AU (1) AU2008223876A1 (es)
CA (1) CA2678794A1 (es)
CL (1) CL2008000617A1 (es)
CO (1) CO6210808A2 (es)
EC (1) ECSP099611A (es)
GT (1) GT200900235A (es)
IL (1) IL200274A0 (es)
MA (1) MA31201B1 (es)
MX (1) MX2009009343A (es)
PE (1) PE20081794A1 (es)
TN (1) TN2009000358A1 (es)
TW (1) TW200843762A (es)
WO (1) WO2008107390A1 (es)
ZA (1) ZA200905472B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
CA2913731C (en) 2013-06-04 2021-05-25 Monosol Llc Water-soluble film sealing solutions, related methods, and related articles
CA3064371A1 (en) * 2016-05-20 2017-11-23 Azure Biotech, Inc. Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102220255B1 (ko) * 2019-08-13 2021-02-26 동국대학교 산학협력단 수술 후 부갑상선기능저하증 개선 또는 치료용 약학 조성물 및 이를 이용한 치료 방법
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
MX2023001438A (es) * 2020-08-04 2023-06-15 Calcilytix Therapeutics Inc Formulaciones de compuestos calciliticos de trifenilo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
US20060052345A1 (en) * 2002-11-04 2006-03-09 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics

Also Published As

Publication number Publication date
ZA200905472B (en) 2010-04-28
TN2009000358A1 (en) 2010-12-31
IL200274A0 (en) 2010-04-29
WO2008107390A1 (en) 2008-09-12
ECSP099611A (es) 2009-10-30
PE20081794A1 (es) 2009-01-09
GT200900235A (es) 2010-03-15
AU2008223876A1 (en) 2008-09-12
US20100022565A1 (en) 2010-01-28
MX2009009343A (es) 2009-09-11
CN101621993A (zh) 2010-01-06
KR20090125245A (ko) 2009-12-04
MA31201B1 (fr) 2010-02-01
CA2678794A1 (en) 2008-09-12
CO6210808A2 (es) 2010-10-20
JP2010520179A (ja) 2010-06-10
TW200843762A (en) 2008-11-16
EP1964548A1 (en) 2008-09-03
EP2124893A1 (en) 2009-12-02
CL2008000617A1 (es) 2008-09-12

Similar Documents

Publication Publication Date Title
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ECSP088239A (es) Composición de liberación de fármaco sostenida
BR112018067586A2 (pt) composição administrável oralmente
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BRPI0514474A (pt) multiparticulados
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
GT200000219A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
AR112480A1 (es) Composiciones de glp-1 y sus usos
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
ECSP088240A (es) Composición de trazodona para administración una vez por día
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2010005013A (es) Composiciones intranasales.
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
BRPI1011071B8 (pt) uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero
CL2008000674A1 (es) Compuestos derivados de 1,4-diarilacetidinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como agente reductor de los niveles de colesterol, para el tratamiento de trastornos del metabolismo lipidico, aterosclerosis
AR052033A1 (es) Composicion farmaceutica que comprende inhibidor de topoisomerasa i

Legal Events

Date Code Title Description
FB Suspension of granting procedure